Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.59 USD
-0.06 (-3.64%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.60 +0.01 (0.63%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ATNM 1.59 -0.06(-3.64%)
Will ATNM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATNM
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
Other News for ATNM
Is ATNM likely to continue lower? 50 Day Moving Average Resistance shows up after dropping 3.64%
Is ATNM setting up for a drop? 20 Day Moving Average Resistance shows up after gaining 2.48%
ATNM Fell Below 50 Day Moving Average on September 17
ATNM Crossed Above 50 Day Moving Average on September 16
Is ATNM set to breakout? NR7 shows up after dropping 0.61%